Repligen/$RGEN
1D1W1MYTD1Y5YMAX
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
- Ticker
- $RGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,000
- Headquarters
- Waltham, United States
- Website
- www.repligen.com
Repligen Metrics
BasicAdvanced
$10B
249.43
$0.73
1.06
-
Price and volume
Market cap
$10B
Beta
1.06
52-week high
$188.73
52-week low
$100.99
Average daily volume
1.2M
Financial strength
Current ratio
9.05
Quick ratio
7.298
Long term debt to equity
31.8
Total debt to equity
32.715
Interest coverage (TTM)
2.74%
Profitability
EBITDA (TTM)
144.101
Gross margin (TTM)
53.84%
Net profit margin (TTM)
5.29%
Operating margin (TTM)
8.32%
Effective tax rate (TTM)
20.35%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
1.40%
Return on equity (TTM)
1.99%
Valuation
Price to earnings (TTM)
249.43
Price to revenue (TTM)
13.062
Price to book
4.86
Price to tangible book (TTM)
15.8
Price to free cash flow (TTM)
93.1
Free cash flow yield (TTM)
1.07%
Free cash flow per share (TTM)
1.955
Growth
Revenue change (TTM)
16.49%
Earnings per share change (TTM)
-383.98%
3-year revenue growth (CAGR)
3.31%
10-year revenue growth (CAGR)
23.45%
3-year earnings per share growth (CAGR)
-30.60%
10-year earnings per share growth (CAGR)
11.30%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Repligen News
AllArticlesVideos
Repligen Q2 Earnings Call Highlights
MarketBeat1 month ago
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Business Wire1 month ago
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
MarketBeat1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.